🚀 VC round data is live in beta, check it out!
Biofarm Valuation Multiples
Discover revenue and EBITDA valuation multiples for Biofarm and similar public comparables like Protara Therapeutics, Coherus Oncology, Polaryx Therapeutics, Eledon Pharmaceuticals and more.
Biofarm Overview
About Biofarm
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
Founded
1990
HQ
Employees
373
Website
Sectors
Financials (FY)
EV
$255M
Biofarm Financials
Biofarm reported last fiscal year revenue of $74M and EBITDA of $31M.
In the same fiscal year, Biofarm generated $63M in gross profit, $31M in EBITDA, and $23M in net income.
Biofarm P&L
In the most recent fiscal year, Biofarm reported revenue of $74M and EBITDA of $31M.
Biofarm expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $74M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $63M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 86% | XXX | XXX | XXX |
| EBITDA | — | XXX | $31M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 33% | XXX | XXX | XXX |
| Net Profit | — | XXX | $23M | XXX | XXX | XXX |
| Net Margin | — | XXX | 32% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Biofarm Stock Performance
Biofarm has current market cap of $294M, and enterprise value of $255M.
Market Cap Evolution
Biofarm's stock price is $0.30.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $255M | $294M | -1.1% | XXX | XXX | XXX | $0.02 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialBiofarm Valuation Multiples
Biofarm trades at 3.5x EV/Revenue multiple, and 8.2x EV/EBITDA.
Biofarm Financial Valuation Multiples
As of April 18, 2026, Biofarm has market cap of $294M and EV of $255M.
Equity research analysts estimate Biofarm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Biofarm has a P/E ratio of 12.6x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $294M | XXX | $294M | XXX | XXX | XXX |
| EV (current) | $255M | XXX | $255M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 3.5x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 8.2x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 10.4x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 4.0x | XXX | XXX | XXX |
| P/E | — | XXX | 12.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Biofarm Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Biofarm Margins & Growth Rates
Biofarm's revenue in the last fiscal year grew by 11%.
Biofarm's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Biofarm Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 42% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | 32% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 52% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Biofarm Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Biofarm | XXX | XXX | XXX | XXX | XXX | XXX |
| Protara Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Coherus Oncology | XXX | XXX | XXX | XXX | XXX | XXX |
| Polaryx Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Eledon Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| C4 Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Biofarm M&A Activity
Biofarm acquired XXX companies to date.
Last acquisition by Biofarm was on XXXXXXXX, XXXXX. Biofarm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Biofarm
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialBiofarm Investment Activity
Biofarm invested in XXX companies to date.
Biofarm made its latest investment on XXXXXXXX, XXXXX. Biofarm invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Biofarm
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Biofarm
| When was Biofarm founded? | Biofarm was founded in 1990. |
| Where is Biofarm headquartered? | Biofarm is headquartered in Romania. |
| How many employees does Biofarm have? | As of today, Biofarm has over 373 employees. |
| Is Biofarm publicly listed? | Yes, Biofarm is a public company listed on Bucharest Stock Exchange. |
| What is the stock symbol of Biofarm? | Biofarm trades under BIO ticker. |
| When did Biofarm go public? | Biofarm went public in 1996. |
| Who are competitors of Biofarm? | Biofarm main competitors are Protara Therapeutics, Coherus Oncology, Polaryx Therapeutics, Eledon Pharmaceuticals. |
| What is the current market cap of Biofarm? | Biofarm's current market cap is $294M. |
| What is the current revenue of Biofarm? | Biofarm's last fiscal year revenue is $74M. |
| What is the current EV/Revenue multiple of Biofarm? | Current revenue multiple of Biofarm is 3.5x. |
| Is Biofarm profitable? | No, Biofarm is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.